Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation.
Olivier HanonJean-Sébastien VidalGeorge Pisica-DonoseGaldric OrvoënJean-Philippe DavidEdouard ChaussadeLaure CaillardLaura W de JongNicolas BoullocheUlric VinsonneauStéphane BouéePierre Krolak-SalmonLaurent FauchierPierre JouannyGuillaume SaccoFabienne BellarbreJoël BelminFrançois PuisieuxMatthieu LilamandElena PaillaudAnne Sophie Boureaunull nullPublished in: Heart (British Cardiac Society) (2020)
Our study findings indicate that bleeding risk, largely driven by lower risk of intracerebral bleeding, is lower with rivaroxaban than with VKA in stroke prevention in patients ≥80 years old with non-valvular AF.
Keyphrases